Semaglutide (Ozempic) is associated with a markedly higher risk of non-arteritic anterior ischaemic optic neuropathy (NAION), which can cause blindness (HR 4.28 in diabetes).
Original statement
سيماغلوتيد (أوزيمبيك) ارتبط بزيادة خطر اعتلال العصب البصري الأمامي الإقفاري غير الشرياني (NAION، اعتلال قد يسبب العمى) لدى مرضى السكري والسمنة مقارنة بالشواهد المطابقة.
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Semaglutide (Ozempic) is associated with a markedly higher risk of non-arteritic anterior ischaemic optic neuropathy (NAION), which can cause blindness (HR 4.28 in diabetes).
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (not Elawady)
- Origin
- https://eltayebat.com/rule/oral-diabetes-drugs/
- Attribution uncertainty
- Editorial narrative and study selection written by the archive operators.
- Claimed health effect
NAION (optic nerve infarction)
- Population concerned
Semaglutide users
- Geographic restriction by Elawady
none found
Scientific assessment
Potentially true – Some evidence points in favour of the statement, but it is not sufficient for a clear judgement.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
Semaglutide raises NAION risk.
2. What is demonstrably correct?
Hathaway et al.: 36-month cumulative incidence 8.9% vs 1.8%, HR 4.28 (1.62-11.29) in T2D; HR 7.64 in obesity (A-ODD-16). A 2026 Bayesian meta-analysis found RR 2.52 (95% CrI 1.56-4.72) and incidence of 118 per 100,000 semaglutide users (I-ODD-15). ADA 2026: 'monitor for NAION during eye examinations' (I-ODD-16).
3. What is wrong or exaggerated?
The first study came from a neuro-ophthalmology referral registry, where NAION patients are over-represented, producing very high incidences (8.9%) not seen in population data (A-ODD-16 vs I-ODD-15). Another 2026 meta-analysis found no consistent overall increase (pooled aHR 1.63, 0.88-2.39) and judged the evidence low to very low certainty (I-ODD-14).
4. What remains unclear?
Causality and size of risk.
5. Which studies support it?
6. Which studies contradict it?
7. What applies to Germany and Europe?
EMA's safety committee reviewed NAION in 2025 (statement not fetched in this audit; verified: false).
8. What is known about Egypt?
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. What practical conclusion is appropriate?
Sudden painless vision loss on semaglutide needs urgent eye examination. A possible rare risk should be part of informed consent.
Assessment details
- Rationale for certainty of evidence
First signal from a single-centre referral cohort with few events (17 vs 6). Subsequent meta-analyses conflict: one found RR 2.52 (low-to-moderate certainty), another found no consistent increase (aHR 1.63, CI 0.88-2.39; low to very low certainty). ADA 2026 advises monitoring for NAION. Absolute risk is low (about 1 per 1,000 users in pooled data).
- Source quality
Archive editorial citing one observational study.
- Regional transferability
Universal.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Some studies suggest that semaglutide may slightly increase the risk of a rare stroke of the optic nerve, which can damage sight. The first study probably overestimated the risk, and later studies disagree on whether there is a real increase. If it exists, it is roughly one case per thousand users. Sudden vision loss should be checked immediately.
Studies on this claim
Studies supporting the claim (3)
-
Semaglutide and optic nerve stroke
Hathaway JT et al.. JAMA Ophthalmol 2024 · PMID 38958939 · DOI 10.1001/jamaophthalmol.2024.2296Cohort studycited by the Tayebat archiveabstract only checked★ key studyIn an eye-clinic registry, semaglutide users had about 4 times more NAION, but numbers were small.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Semaglutide and NAION risk
- How was the study done?
Retrospective matched cohort from a neuro-ophthalmology registry
- How many people, animals or samples were studied?
16,827 screened; 710 T2D, 979 overweight/obese; Patients evaluated by neuro-ophthalmologists at one academic institution
- What was actually found?
HR 4.28 (T2D).
- How large was the observed effect?
HR 4.28 (1.62-11.29)
- What do the results mean in everyday life?
Possible rare eye risk.
- What are the study's limitations?
Referral population (selection bias); Few events; Single centre
- What does it say about Elawady's specific claim?
Supports C-ODD-10.
- Do the results apply to Germany and Europe?
US data.
- What can explicitly not be concluded from this study?
Causation or population incidence.
-
Semaglutide and NAION: pooled analysis 2
Dhivagaran T et al.. Neurology 2026 · PMID 42060879 · DOI 10.1212/WNL.0000000000214864Meta-analysisindependent cross-checkabstract only checkedRisk about 2.5 times higher, but absolute risk about 1 per 1,000 users.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
GLP-1 RA use and NAION risk
- How was the study done?
Systematic review and Bayesian meta-analysis (ROBINS-I, GRADE)
- How many people, animals or samples were studied?
5 studies; 1,593,554 patients; GLP-1 RA users vs non-users
- What was actually found?
RR 2.52.
- How large was the observed effect?
RR 2.52 (1.56-4.72)
- What do the results mean in everyday life?
Possible rare eye risk.
- What are the study's limitations?
Observational inputs; Heterogeneous incidence
- What does it say about Elawady's specific claim?
Supports C-ODD-10.
- Do the results apply to Germany and Europe?
Multinational.
- What can explicitly not be concluded from this study?
Causation definitively.
-
ADA guideline 2026: diabetes medicines
American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009Guideline / position statementindependent cross-checkfull text checked★ key studyInsulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Pharmacologic glycaemic treatment
- How was the study done?
Clinical practice guideline (ADA Standards of Care 2026, Section 9)
- How many people, animals or samples were studied?
not applicable; People with type 1 and type 2 diabetes
- What was actually found?
See results.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Medicines chosen by benefit-risk.
- What are the study's limitations?
Partially read
- What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-10, C-ODD-06; supports C-ODD-07, C-INS-11.
- Do the results apply to Germany and Europe?
Consistent with ADA/EASD consensus.
- What can explicitly not be concluded from this study?
Not applicable.
No study in this group is marked as key.
Studies contradicting or limiting the claim (1)
-
Semaglutide and NAION: pooled analysis 1
Abdelaal A et al.. Ophthalmology 2026 · PMID 41692115 · DOI 10.1016/j.ophtha.2026.02.013Meta-analysisindependent cross-checkabstract only checkedNo consistent overall increase found; possible increase in diabetes patients; evidence weak.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Semaglutide vs non-GLP-1 RA therapy and NAION
- How was the study done?
Systematic review and meta-analysis of observational studies with GRADE
- How many people, animals or samples were studied?
6 studies; 4,831,654 participants; Adults on semaglutide or comparators
- What was actually found?
aHR 1.63 (n.s.).
- How large was the observed effect?
aHR 1.63 (0.88-2.39)
- What do the results mean in everyday life?
Risk uncertain.
- What are the study's limitations?
Observational inputs; Extreme heterogeneity
- What does it say about Elawady's specific claim?
Limits C-ODD-10.
- Do the results apply to Germany and Europe?
Includes multinational data.
- What can explicitly not be concluded from this study?
Causation.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
EMA's safety committee reviewed NAION in 2025 (statement not fetched in this audit; verified: false).
Egypt
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
What applies in my country?
General scientific assessment
Potentially true A possible rare eye risk with conflicting evidence.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.. Hathaway JT et al.. JAMA Ophthalmol 2024 · PMID 38958939 · DOI 10.1001/jamaophthalmol.2024.2296
- Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis.. Dhivagaran T et al.. Neurology 2026 · PMID 42060879 · DOI 10.1212/WNL.0000000000214864
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
- Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.. Abdelaal A et al.. Ophthalmology 2026 · PMID 41692115 · DOI 10.1016/j.ophtha.2026.02.013